成都做静脉曲张手术需要多少钱成都治疗下肢动脉硬化便宜的医院,成都怎么治疗肝血管瘤较好,成都有专业治疗老烂腿的医院,成都哪个睾丸精索静脉曲张医院比较好,静脉扩张治疗价格成都,成都血糖足病的治疗,成都婴儿血管瘤哪家医院比较好

VANCOUVER, Sept. 17 (Xinhua) -- The fourth International Health Qigong Tournament and Exchange kicked off the competition portion of the Vancouver event Saturday to showcase the health benefits of this increasingly popular activity.At a gala opening ceremony in the War Memorial Gymnasium at the University of British Columbia, the biennial tournament was being held outside of China for the first time in an effort to promote the exercise that involves controlled breathing, body postures, movement and mental concentration.The Vancouver tournament has attracted 44 Health Qigong groups from 25 countries and regions, 327 participants in all. The event was last held in Shanghai in 2009.Xiao Min, the All-China Sports Federation vice president, said after three successful events in China, it was important to explore the possibilities of rotating the host venues around the world to boost the exposure of Health Qigong to a wider audience, effectively strengthening the interaction of the Eastern and Western cultures.Calling it "one of the best Chinese traditional sports," Xiao added, "we still have a long way to go in promoting Health Qigong. However, we will try our best to promote it so as to bring health benefits to more people in the world."Sending a message read by Vancouver-based federal politician Wai Young, Canadian Prime Minister Stephen Harper said such a tournament would allow people to "cultivate their interest in and learn more about the benefits of this ancient Chinese healing system.""I would like to commend the organizing committee for putting together a program that promotes cultural exchange and encourages others to embrace Qigong teachings and practices for health, fitness and personal growth. I'm certain that the enthusiasts will make the most of this exciting opportunity and will leave inspired to put what they have learned into practice," wrote Harper, who will be making his second official visit to China later this year.In his speech to the dignitaries and public gathered for the opening ceremony, Liang Shugen, the Chinese Consul General in Vancouver, said it didn't matter who won medals during the competition as everybody participating was a winner."However, it is all the more important that your group build up friendship among the different peoples from different countries, so therefore I wish you all do your best and hope that through this competition you bring the friendship of the Chinese people, of the people from different countries, back to your home country and it is such a course that will be building a harmonious world."With participants representing countries and regions from North America, Europe, Australia, South America, Asia and all over China, which has competitors from 10 provinces, as well as Macau and Hong Kong, the eight-day tournament is providing an extensive overview of what Health Qigong is about.In addition to the two-day competition taking place over the weekend, there is also a referee clinic, a Duan examination and training sessions in the different Health Qigong disciplines, Yi Jinjing, Wu Qinxi, Liu Zijue and Ba Duanjin, among them.Ken Low, who is considered Mr Wushu in Canada, has been instrumental in organizing the Vancouver event. As the president of the Canada International Health Qigong Association he said people need to know about what's involved in the exercise and how it's different from traditional martial arts."It is more than fitness, it's actually mental and physical. It builds inner strength and it builds your, strengthens your joints and muscles and tendons, particularly in your neck area, your shoulders, your spine and your inner organs and your breathing and your focus," he said."So it's not a martial arts, although it is connected somewhat to martial arts because the movements have no self-defence meanings. All the movements are designed to enhance your health."One person who turned to the exercise for health reasons is Diane Hynes. A member of the 12-strong team representing the USA Health Qigong Association, the 50-year-old New Jersey native offers classes in Health Qigong with a cliental of students ranging from five to 84 years.She explained Qigong "helps refine that movement of our eternal energy and makes more as you breathe and move. It has to do with your breath, your ability to relax, bringing your mind to your heart and really moving it out, the energy out to the limbs. That's why it helps with sleep and stress."Hynes, who looked healthy and fit, said she realizes that she is influencing others who want to know what the mother of nine-year-old is doing to look good."And I'm not taking drugs to look well or having surgery," she said, adding the practice is destined to get bigger among westerners as the Baby Boomer generation ages and puts greater emphasis on health. ( "Medication can help for awhile but that takes from you as well, that takes from your energy. This just helps to build energy and move it in your body. Because the thing is, in Chinese medicine, it's about movement, everything's a flow and moving in a circle so it's a give and take."It's a movement and if you are not moving in harmony and you're stuck and stagnant then you are going to be uneasy or diseased or unwell. You're not necessarily sick but you're stuck."

WASHINGTON, Aug. 18 (Xinhua) -- Black scientists were significantly less likely than their white counterparts to receive research funding from the National Institutes of Health (NIH), according to an analysis of data from 2000 to 2006.University of Kansas Professor of Economics Donna Ginther was the lead author on the study commissioned by the NIH, which will appear Friday in journal Science.The researchers found a 10 percentage point gap in research funding -- even after taking into consideration demographics, education and training, employer characteristics, NIH experience and research productivity. For example, for every 100 grants submitted to NIH, 30 grants from white applicants were funded, compared to 20 grants for black applicants.Applications for NIH funding go through peer review that considers the significance, innovation and approach of grant applications, the investigator(s) and the research environment. About half of the applications are determined to be worth scoring. Among those scored, budgets and NIH Institutes priorities determine which applications are funded. Priorities can vary by year and by Institute.The study found that applications from black researchers were less likely to be scored and on average had worse scores. After controlling for the score of the grant, there were no race or ethnicity differences in funding.Applicants self-identify race, ethnicity and gender, but that information is not available during the peer review. However, biographical facts that are included in the review materials can provide clues to the identity of the applicants.The research suggests it is possible that cumulative advantage may explain the funding differences."Small differences in access to research resources and mentoring during training or at the beginning of a career may accumulate to become large between-group differences," the paper says.Additionally, the paper suggests further research is needed to determine why black researchers are less likely to be funded.NIH Director Francis Collins and Principal Deputy Director Lawrence Tabak call the findings unacceptable and commit to immediate action by the NIH."NIH commissioned this study because we want to learn more about the challenges facing the scientific community and address them head on. The results of this study are disturbing and disheartening, and we are committed to taking action," said Collins in an accompanying commentary. "The strength of the U.S. scientific enterprise depends upon our ability to recruit and retain the brightest minds, regardless of race or ethnicity. This study shows that we still have a long way to go."NIH initiated the study in 2008 to determine if researchers of different races and ethnicities with similar research records and affiliations had similar likelihoods of being awarded a new NIH research project grant.

LOS ANGELES, June 5 (Xinhua) -- U.S. researchers have developed two new drugs that can prolong the lives of patients with advanced melanoma, it was announced on Sunday.Research on both drugs was presented at the on-going annual meeting of the American Society of Clinical Oncology in Chicago, according to HealthDay News.This is the first big news in years for treatment of melanoma, one of the deadliest forms of skin cancer and one that is notoriously difficult to treat, let alone cure, the report said.The first treatment, vemurafenib, inhibits a gene mutation harbored in half of all melanoma patients, but is not yet approved by the U.S. Food and Drug Administration.The other drug, Yervoy (ipilumumab), is an immune system therapy that won approval in March."The March FDA approval of ipilumumab (Yervoy) was the first new drug approval for melanoma in 13 years," said Tim Turnham, executive director of the Melanoma Research Foundation.The two drugs were developed by researchers at Memorial Sloan- Kettering Cancer Center in New York City, the report said."This is really a huge step toward personalized care in melanoma," Dr. Paul Chapman, lead author of the first study and the attending physician in the melanoma/sarcoma service at Memorial Sloan-Kettering, said in a statement. "This (vemurafenib) is the first successful melanoma treatment tailored to patients who carry a specific gene mutation in their tumor, and could eventually become one of only two drugs available that improves overall survival in advanced cancers.""Having two trials that show a benefit in survival in patients with melanoma, both of these in first-line settings -- we weren't here just a few years ago," said Dr. Stephen Hodi, director of the Melanoma Center at Dana Farber Cancer Institute in Boston. "These are huge, paradigm-shifting results for the field."In the vemurafenib trial, sponsored by the drug's makers, researchers randomly assigned 675 patients with advanced, inoperable melanoma to receive either the chemotherapy drug dacarbazine or vemurafenib. Vemurafenib targets the V600E mutation in the BRAF gene.At the three-month mark, patients taking vemurafenib were 63 percent less likely to die and 74 percent less likely to die or see their cancer return, compared to patients taking dacarbazine alone.Few patients had side effects in the vemurafenib group, although some did develop squamous cell carcinoma, a less dangerous form of skin cancer.This is the first drug that has been proven superior to chemotherapy in this group of hard-to-treat patients, the researchers said."There was such a substantial benefit that we recommended that patients cross over," Chapman said at a Sunday news briefing. "It' s unprecedented to report a trial this early. The median follow-up time was three months." Yet the differences between the two groups became evident almost immediately.Dr. Lynn Schuchter, co-moderator of the briefing and division chief of hematology-oncology at Abramson Cancer Center of the University of Pennsylvania in Philadelphia, said symptoms subsided in some patients almost immediately, enabling them to cut back on pain medication in just 72 hours."The median time to progression with dacarbazine was 1.6 months versus three months with vemurafenib, which is a huge difference," said Chapman.In the second study, about 500 patients were randomly picked to receive Yervoy plus dacarbazine or dacarbazine alone.Those taking both drugs lived a median of 11.2 months compared to 9.1 months for those taking dacarbazine alone. Time to recurrence of disease was about the same for both groups: 2.8 months and 2.6 months, respectively.Almost half of those taking the combination therapy were alive after one year, compared to 36.3 percent in the other group. After two years, the rates were 28.5 percent and 17.9 percent, respectively.By three years out, 20.8 percent of those in the combination group were alive compared with 12.2 percent of those taking chemotherapy alone.This is the first study to combine chemotherapy and immunotherapy both safely and effectively.A study to test vemurafenib in combination with Yervoy has already begun, according to HealthDay News.

BEIJING, July 26 (Xinhuanet) -- Seven of the 20 top selling American prescription drugs will lose their patents by the end of next year, making way for less expensive generic versions, according to media reports.It's a shift that could save consumers billions of dollars -- assuming those big-ticket medications are willing to give up a trusted brand name for an off-label replacement.The prices of medications such as cholesterol-fighting Lipitor and blood thinner Plavix are expected to go down significantly, according to the U.S. Food and Drug Administration (FDA).Lipitor will lose its patent in November. When that patent expires, people are advised to buy atorvastatin, the generic equivalent. Other brand names include the anti-psychotic Zyprexa and the rheumatoid arthritis and psoriasis drug Enbrel, of which the patent will expire in October and October of next year, respectively.Over the next 10 years, an estimated 120 more brand-name prescription drugs will lose their patents in the U.S.

SAN FRANCISCO, June 28 (Xinhua) -- Google Android chief Andy Rubin said on Tuesday that the activations of Android-powered devices are growing at a rate of 4.4 percent on a weekly basis, with over 500,000 devices activated each day worldwide."There are now over 500,000 Android devices activated every day, and it's growing at 4.4 percent w/w," tweeted Rubin, Google's Senior Vice President of Mobile who oversees the development of Android, the open-source operating system for smartphones.Last month, Google said at its annual developer conference Google I/O that 400,000 Android devices were being activated each day, compared with 300,000 daily activations in December and 100, 000 in May 2010.More research data have shown Android system's soaring market share and popularity. Earlier this month, Internet market research company ComScore reported that Android remained the No. 1 smartphone operating system in the United States over the three months ending in April. The system captured 36.4 percent of U.S. smartphone subscribers, while Apple's iOS system for iPhone had 26 percent of all smartphone users.In April, market research company Gartner said in a forecast that the Android operating system will own 49.2 percent of the global smartphone market and Apple's iOS will have an 18.9-percent share in the second place.